Compare Docusign Inc (DOCU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Docusign Inc trades at $71.4 (market cap $13.35B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.6× Docusign Inc's market cap, and Docusign Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DOCU | VRTX | |
|---|---|---|
Market Cap | $13.35B | $128.16B |
Volume | 3,158,858 | 806,603 |
Sector | Technology | Health |
52-Week High | $73.14 | $557.96 |
52-Week Low | $41.75 | $407.37 |
Typical Hold Time | 71 Days | 120 Days |
Enterprise Value | $12.76B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DocuSign (DOCU) trades at $68.9, up 1.0% on the day, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.16 surpassing the $1.09 forecast. Revenue growth remains solid, reaching $2.98B in 2025, while profitability has improved significantly, with net income margin at 9.82%. Recent news highlights strong momentum, including a 50.8% stock surge over three months and leadership in IDC's integrated signing workflow software assessment (IDC MarketScape, August 2026).
The outlook for DOCU is cautiously optimistic, driven by AI-powered Intelligent Agreement Management adoption and operating leverage. However, risks include saturation in the e-signature market, insider selling activity, and a high P/E ratio of 42.01. Analyst consensus is mixed, with a Hold rating predominating (64.29%) and a price target of $68.75, slightly below the current price. Investors should weigh strong cash flow generation against valuation concerns and competitive pressures.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
